CLCSCell Source, Inc.

About Cell Source, Inc. (CLCS)

Cell Source, Inc. (CLCS) is a Biotechnology company headquartered in New York, NY, United States whose shares trade over-the-counter on the OTCQB tier.

We are engaged in the development and commercialization of proprietary technology which we license from the Weizmann Institute of Science. We are currently sponsoring both research and a clinical trial in at the University of Texas MD Anderson Cancer Center. Our principal operations are focused on developing innovative immunotherapy products focused on the effective treatment of blood cancers and nonmalignant blood disorders as well as the facilitation of safer and more accessible organ transplantation. Our key areas of focus in the near term include: significantly safer haploidentical stem cell transplants under reduced immune suppression and while avoiding graft versus host disease; persistent and efficacious off-the-shelf CAR-T cell therapy; and kidney transplantation without the need for a full donor match while avoiding ongoing post-transplant antirejection treatments.

Products and services

The company is developing cell therapy treatments for cancer, stem cell and organ transplantation, and the treatment of congenital, nonmalignant disorders. The company is in the clinical stage, and as such, does not have any products or services for sale at this time.

CLCS key facts

Ticker symbol

CLCS

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

New York, NY, United States

Country of incorporation

US

Year of incorporation

2012

Employees

1

Estimated market cap

$12.61M (as of Apr 10, 2025)

Shares outstanding

45,038,244

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Cell Source, Inc. leadership

• Itamar Shimrat — President, CEO, Treasurer, Company Secretary
• Philip Dowd Forlenza — General Counsel

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with C